Methods
Two hundred patients received 600 mg of clopidogrel and underwent platelet reactivity testing with VerifyNow P2Y12 (VN) at 6 to 24 h after PCI. High on-treatment platelet reactivity (HOPR) was defined as platelet reactivity units ≥235 for VN. CRI was defined as serum creatinine ≥2.0 mg/dl on presentation with previously diagnosed renal insufficiency treated by a physician. Univariable association between CRI and HOPR was evaluated with the χ 2 test, and multivariable association was evaluated with logistic regression.
Methods
Two hundred patients received 600 mg of clopidogrel and underwent platelet reactivity testing with VerifyNow P2Y12 (VN) at 6 to 24 h after PCI. High on-treatment platelet reactivity (HOPR) was defined as platelet reactivity units ≥235 for VN. CRI was defined as serum creatinine ≥2.0 mg/dl on presentation with previously diagnosed renal insufficiency treated by a physician. Univariable association between CRI and HOPR was evaluated with the χ 2 test, and multivariable association was evaluated with logistic regression.
Results
Fourteen percent of patients had a history of CRI. Forty-five percent of patients with CRI had HOPR compared to 24% of patients without HOPR ( P =.02). Patients with CRI were also older (69 vs. 62 years, P =.006) and more likely to be diabetic (55% vs. 31%, P =.01) or have a history of congestive heart failure (45% vs. 13%, P <.001) ( Table 1 ). Following multivariable adjustment for diabetes, congestive heart failure, presentation with acute myocardial infarction and body mass index, CRI remained significantly associated with HOPR.
